8 employees
Kynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism.
2020
$8.5M
from 4 investors over 4 rounds
Kynos Therapeutics Ltd. raised $8.5M on April 7, 2022
Investors: Epidarex Capital, Scottish Enterprise and IP Group plc
Kynos Therapeutics Ltd. raised $3.3M on April 7, 2022
Investors: Innovate UK